Parsabiv Could Allow Amgen To Maintain Control Of Calcimimetics Market

 
• By Michael Cipriano

Amgen's oral calcimimetic Sensipar faces generic competition in 2018, but the new intravenuous Parsabiv has advantages that could make it the more popular alternative.

Lion
Amgen looks set to retain market dominance with Parsabiv • Source: Shutterstock

More from Drug Pricing

More from Scrip